Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 20 (2006), Issue 11, Pages 725-734

Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop

Kymberly DS Watt,1 Kelly Burak,2 Marc Deschênes,3 Les Lilly,4 Denis Marleau,5 Paul Marotta,6 Andrew Mason,7 Kevork M Peltekian,1 Eberhard L Renner,8 Eric M Yoshida,9 and for the Canadian Transplant Hepatology Outcomes Research Network

1Dalhousie University, Halifax, Nova Scotia, Canada
2University of Calgary Liver Unit, Calgary, Alberta, Canada
3McGill University Health Centre, Montreal, Quebec, Canada
4University of Toronto, University Health Network Liver Transplant Program, Toronto, Ontario, Canada
5Saint Luc Hospital, University of Montreal, Montreal, Quebec, Canada
6University of Western Ontario Liver Unit, London Health Sciences, London, Ontario, Canada
7University of Alberta, Edmonton, Alberta, Canada
8University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada
9University of British Columbia, Vancouver, British Columbia, Canada

Received 19 December 2005; Accepted 2 February 2006

Copyright © 2006 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles’ heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.